• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Calumet’s Q2 Revenue Growth but Deeper H1 Loss Altering The Investment Case For Calumet (CLMT)?

    Simply Wall St·08/17/2026 13:20:51
    Listen to the news
    • Calumet, Inc. has reported past second-quarter 2026 results, with sales rising to US$1,445.1 million from US$1,026.6 million a year earlier, while quarterly net loss narrowed to US$95.9 million and basic loss per share from continuing operations improved to US$1.09 from US$1.70.
    • Over the first half of 2026, however, Calumet’s net loss widened to US$412.9 million despite higher sales of US$2,474.9 million, highlighting ongoing profitability pressures even as revenue grows.
    • We’ll now examine how Calumet’s higher second-quarter sales but larger year-to-date net loss affect the company’s existing investment narrative.

    Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

    Calumet Investment Narrative Recap

    To own Calumet today, you have to believe that the shift toward higher value renewables and specialty products can eventually outweigh the drag from its legacy operations and leverage. The latest results show stronger second quarter sales and a narrower quarterly loss, but the much larger first half net loss keeps balance sheet risk and cash generation as the key near term swing factors. Overall, this update does not materially change the central short term catalyst or the main risk.

    Among recent developments, Calumet’s July decision to fully redeem US$100.0 million of 9.75% senior notes due 2028 stands out against these earnings. That move, combined with the earlier refinancing and ABL extension to 2031, underlines how central debt management is to the story as investors watch for any earnings improvement to translate into lower interest costs and better financial resilience around projects such as MaxSAF.

    Yet against the promise of renewables growth, the combination of widening year to date losses and substantial debt still poses a risk that investors should be aware of...

    Read the full narrative on Calumet (it's free!)

    Calumet's narrative projects $5.3 billion revenue and $226.9 million earnings by 2029. This requires 8.6% yearly revenue growth and a $415.7 million earnings increase from -$188.8 million today.

    Uncover how Calumet's forecasts yield a $38.80 fair value, a 19% downside to its current price.

    Exploring Other Perspectives

    CLMT 1-Year Stock Price Chart
    CLMT 1-Year Stock Price Chart

    Some of the most optimistic analysts were expecting revenue of about US$6.8 billion and earnings of roughly US$152.8 million, so when you compare that to Calumet’s widening first half 2026 loss and the ongoing leverage concerns, it highlights how different your view might be if you lean into that upside scenario or focus instead on the risk that high capex and aging assets could keep pressure on results.

    Explore 2 other fair value estimates on Calumet - why the stock might be worth 19% less than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.